Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Capecitabine (Primary) ; Neratinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 09 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 09 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 08 Dec 2018 Results (n=8, data cut off: July 2018) presented at the 41st Annual San Antonio Breast Cancer Symposium